ALK and neoplasm: As a result of these findings Crescenzo et al. demonstrated that JAK/STAT3 inhibition impaired tumor growth in a preclinical ALK-negative ALCL-patient derived tumorgraft model, providing new potential therapeutic targets for ALK negative treatment [71].